Equities researchers at StockNews.com started coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Rating) in a report released on Saturday. The firm set a "sell" rating on the biotechnology company's stock.
Genocea Biosciences Stock Performance
Shares of GNCA stock opened at $0.01 on Friday. The business's fifty day moving average price is $0.01 and its 200 day moving average price is $0.35. Genocea Biosciences has a 1-year low of $0.01 and a 1-year high of $2.16. The firm has a market capitalization of $657,820.80, a PE ratio of -0.02 and a beta of 1.96. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.35 and a quick ratio of 1.35.
Get Genocea Biosciences alerts:Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Genocea Biosciences stock. Acadian Asset Management LLC acquired a new position in shares of Genocea Biosciences, Inc. (NASDAQ:GNCA – Get Rating) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 21,741 shares of the biotechnology company's stock, valued at approximately $25,000. 9.31% of the stock is owned by institutional investors and hedge funds.
About Genocea Biosciences
(Get Rating)Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.
Recommended Stories
- Get a free copy of the StockNews.com research report on Genocea Biosciences (GNCA)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.